North America Cell Surface Markers Market

North America Cell Surface Markers Market Size (2023 to 2028)

The size of the cell surface markers market in the North American region is expected to grow at a CAGR of 7.53% from 2023 to 2028 and be worth USD 346.81 million by 2028 and USD 241.24 million in 2023.

Due to factors such as increased financing for life sciences research, a high prevalence of cancer, increasing demand for precision medicine, higher usage of diagnostics, and technological advancements related to increased throughput and automation and expansion in stem cell and neurobiology research, the market for cell surface markers in North American is expected to rise at a healthy growth rate during the forecast period. In addition, the market for cell surface markers in North America is further being driven by a growing acceptance of cell surface markers analysis by key markets and confirmed efficacy in clinical laboratories.

Furthermore, factors such as more significant market consolidation, simplicity of the analysis process, cost containment of instruments and reagents, and the launch of less expensive products will result in quick acceptance of research in cell surface markers in emerging markets. Furthermore, increased healthcare awareness, affordability, better patient rehabilitation, growth in medical tourism, and lower levels of competition than in developed markets will result in increased demand for cell surface marker identification and associated disease diagnosis and treatment.

Due to the ambiguous cost-benefit ratio, small pharmaceutical companies are increasingly hesitant to invest in highly complex flow cytometers and hematological analyzers. Because drug development is expensive, smaller pharmaceutical companies cannot afford to invest in pricey equipment and consumables. As a result, the market expansion will most likely be restricted. However, the market's development has been stifled by advanced systems and expensive apparatus and reagents needed in cell marker analysis.

This research report on the North American cell surface markers market has been segmented and sub-segmented into the following categories.

By Type:

• T Cell Surface Markers
• NK Cell Surface Markers
• B Cell Surface Markers
• Monocyte Cell Surface Markers

By End-User:

• Clinical Testing Laboratories & Hospitals
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies

By Source:

• Rats
• Mice
• Others

By Country:

• The United States
• Canada
• Rest of North America

North America was the market leader in 2022. The rise in cell surface indicators in personal medication, the rising number of R&D activities, and the increased emphasis on drug development and discovery have contributed to this region's market supremacy. As a result, the largest market for cell surface markers is in North America. The vast market size is due to rapidly rising applications in disease diagnostics, the presence of well-established research institutions, and the biotech market.

In North America, the United States now dominates the cell surface marker market, likely to remain so for a few more years. High healthcare spending, quick technology adoption, and an increasing emphasis on precise and rapid diagnoses drive market growth in the United States. Because the United States has many enterprises in this market, demand from the country is likely to be strong over the forecast period. In addition, the rise in the rate of autoimmune diseases has a beneficial impact on the market's growth. Because cell surface markers are an effective and cost-efficient way of identifying autoimmune health issues, this focus on lowering disease detection costs has a favorable impact on the market. In addition to the previously indicated point, there has been an increase in investment in technical improvements in the healthcare sector during the forecast period. Therefore, the market's expansion is also being aided by advances in healthcare technology.

KEY MARKET PLAYERS:

Companies playing a promising role in the global cell surface markers market profiled in this report are Bio-Rad Laboratories, Inc., Siemens Healthcare Private Limited, Beckman Coulter, Inc., NIHON KOHDEN CORPORATION, Hoffmann-La Roche Ltd, BD, Abcam PLC., QIAGEN, Thermo Fisher Scientific, Abbott, Danaher, GenScript, Merk KGaA, BioLegend, Inc. and Cell Signaling Technology, Inc.